The landscape of healthcare technology in 2026 reveals both progress and caution. AI in drug discovery has advanced, with Novartis using it to design 15 million compounds for Huntington’s disease, ultimately synthesizing 60 candidates. However, no AI-discovered drugs have yet received FDA approval, highlighting a gap between accelerated screening and actual clinical success. Furthermore, health chatbots, while attracting over 40 million daily users, are flagged as a significant safety risk by organizations like ECRI due to poor performance in real-life scenarios and potential for misinformation. The narrative suggests that while AI has made strides in efficiency, its capability in achieving meaningful medical breakthroughs remains limited, reinforcing the role of AI as a supportive tool rather than a substitute for clinical expertise.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://thenextweb.com/news/ai-healthcare-drug-discovery-chatbots-reality
